Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.71 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.57 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27670793 | 0.90 | KEAP1 (0.69) | CYP19A1KEAP1TP53LMNASLC12A2 | |
| SCHEMBL21048461 | 0.88 | KEAP1 (0.81) | CYP19A1KEAP1LMNACA12CA9 | |
| SCHEMBL5960081 | 0.86 | CYP19A1 (0.80) | CYP19A1TP53LMNAGPR17CA12 | |
| SCHEMBL10904384 | 0.86 | CYP19A1 (0.70) | CYP19A1KEAP1TP53LMNASLC12A2 | |
| SCHEMBL5123459 | 0.84 | AKR1C3 (0.77) | CYP19A1TP53LMNAMCL1GPR17 | |
| SCHEMBL407414 | 0.82 | KEAP1 (1.00) | KEAP1LMNASLC12A2SLC12A5CA12 | |
| SCHEMBL13973164 | 0.82 | CYP19A1 (0.63) | CYP19A1KEAP1TP53LMNASLC12A2 | |
| SCHEMBL8789480 | 0.81 | CYP19A1 (0.78) | CYP19A1KEAP1TP53LMNASLC12A2 | |
| SCHEMBL4662845 | 0.81 | KEAP1 (0.76) | CYP19A1KEAP1TP53LMNASLC12A2 | |
| SCHEMBL12530955 | 0.81 | CYP19A1 (0.62) | CYP19A1TP53LMNASLC12A2SLC12A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0104353-B1 | HEAT SENSITIVE RECORD MATERIAL | HODOGAYA CHEMICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | claimed |
| EP-2007760-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007108569-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-09-27 | — | — | WO | disclosed |
| US-7049468-B2 | Modulators of Rho C activity | ICONIX PHARMACEUTICALS, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1453470-A4 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1453470-A1 | MODULATORS OF RHO C ACTIVITY | Iconix Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | ENTELOS HOLDING CORP. | 2003-09-11 | — | — | US | disclosed |
| WO-2003043578-A2 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | RHOC, RHOA, ROCK1 | CYP19A1 993/4885KEAP1 541/4885TP53 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.